Traws Pharma
TRAW
28 hedge funds and large institutions have $1.36M invested in Traws Pharma in 2024 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
17% more funds holding
Funds holding: 24 → 28 (+4)
0.12% more ownership
Funds ownership: 0.35% → 0.48% (+0.12%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
28% less capital invested
Capital invested by funds: $1.88M → $1.36M (-$525K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$674K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$63.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$54.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.1K |
| 5 |
VF
Virtu Financial
New York
|
+$17.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$73.8K |
| 2 |
Two Sigma Investments
New York
|
-$38.4K |
| 3 |
Renaissance Technologies
New York
|
-$32.3K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.1K |
| 5 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
-$677 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CPG
26
Cornerstone Planning Group
Fairfield,
New Jersey
| $12 | – | – | – |
|
27
Qube Research & Technologies (QRT)
London,
United Kingdom
| $1 | – | – | – |
|
|
28
Two Sigma Advisers
New York
| – | -$73.8K | -2,923 | Closed |
|
|
29
Two Sigma Investments
New York
| – | -$38.4K | -1,519 | Closed |
|
30
Fidelity Investments
Boston,
Massachusetts
| – | -$645 | -40 | Closed |
|
|
OPTFSNA
31
Old Point Trust & Financial Services N A
Newport News,
Virginia
| – | -$168 | -7 | Closed |
|
32
Wells Fargo
San Francisco,
California
| – | -$166 | -7 | Closed |
|
33
Simplex Trading
Chicago,
Illinois
| – | +$1.01K | +63 | New |
|
TRAW Hedge Fund Activity: Q2 2024 in Review
28 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q2 2024, worth a combined $1.36M — down 28% from $1.88M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TRAW positions and 5 closed out — a net gain of 4 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $674K. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $73.8K sold.
- 28 institutional investors held Traws Pharma (TRAW) as of Q2 2024, up from 24 in Q1 2024.
- Funds reported $1.36M of Traws Pharma stock for Q2 2024, down 28% quarter-over-quarter.
- 9 funds opened new Traws Pharma positions in Q2 2024 and 5 closed out, a net change of +4 holders.
- The largest Traws Pharma buyer in Q2 2024 was OrbiMed, an estimated $674K added.
- The largest Traws Pharma seller in Q2 2024 was Two Sigma Advisers, an estimated $73.8K sold.
Based on aggregated 13F filings for Q2 2024.